D-LOR Tablet

Oral administration for relief of symptoms associated with seasonal allergic rhinitis, chronic idiopathic urticaria.

Dosage

for adults and adolescents (12 years): 5mg daily with or without meals

Pharmacokinetics studies with desloratadine in the elderly and in patients with renal dysfunction are not yet available.

The available data for loratadine indicated that the elimination half-life of desloratadine may be increased in patients with chronic renal failure. However, dosage reduction in mild to moderate renal impairment is probably not necessary.

Limited pharmacokinetic data suggest that desloratadine 5mg daily is likely to be safe in patients with hepatic dysfunction.

Hypersensitivity to Desloratadine or loratadine or any of its excipients.

In clinical trials desloratadine was generally well tolerated. The most common adverse effects of desloratadine reported are headache, dry mouth and fatigue.

There are no known interactions of desloratadine with other drugs cannot be excluded.

See "special Precaution".

Pregnancy, lactation, severe renal failure.

Desloratadine is a long acting, non-sedating, selective peripheral histamine H1 receptor antagonist. Desloratadine acts by inhibiting the release of pro-inflammatory mediators for human mast cells/basophils.

Desloratadine was more potent than loratadine with respect to in vivo inhibition of histamine induced wheal and flare. It does not really penetrate the central nervous system.

Desloratadine demonstrates H1 receptor specificity including 15-to 50 fold lower affinity for muscarinic receptors compared with H1 receptors.

Clinical studies have demonstrated that desloratadine has a lack of clinically significant cardiovascular toxicity, and unlike most other antihistamines, has decongestant effects.